Easing down your eczema medicine often keeps skin calm, review finds

If your eczema has been calm for a long time on a strong prescription medicine, here is some good news. You may not need the full dose forever. A new review found that lowering the dose, step by step, kept skin under control more often than stopping all at once.

That means fewer shots or pills, and a plan for a lighter routine once your skin has settled down. It is a conversation worth having with your dermatologist.

How the study worked

Researchers searched three major medical databases for studies on lowering or stopping six eczema drugs: dupilumab, tralokinumab, lebrikizumab, abrocitinib, baricitinib and upadacitinib. They pulled together the studies they found, which covered 4375 people with moderate-to-severe atopic dermatitis, the most common form of eczema. The review was published Oct. 14, 2026, in the American Journal of Clinical Dermatology. The studies measured success in different ways, so the numbers below are ranges, and longer studies are on the way.

What they found

In people whose skin was stable, easing down the dose kept the benefits more often than stopping suddenly. Here is the share of people who stayed in control after tapering, drug by drug:

For several of these drugs, more than half of the people kept their results. Lebrikizumab, baricitinib and upadacitinib all had ranges that reached well above 60%, and dupilumab reached as high as 100% in some groups.

The range is wide because people and studies differ. Still, the pattern held: gradual tapering did a better job of preserving results than an abrupt stop.

Who tends to keep control?

The review also looked for clues about who does best. Two signs showed up often. People who started with milder eczema did well. So did people whose skin improved early in treatment.

Some clues were specific to one drug:

• Dupilumab: older age, a lower body mass index and a type of eczema with itchy nodules (prurigo nodularis) were linked to lasting control in some groups.
• Tralokinumab: steady skin across several visits was a better sign than a single good visit.
• Abrocitinib: milder eczema without allergic conditions did best.
• Upadacitinib: relapses were more common after people stopped completely, which makes a gradual plan the one to talk about.

Because the clues differ by drug, your own plan can be built around the medicine you take and how your skin has behaved.

What you can do today

Keep taking your medicine exactly as prescribed until you and your dermatologist agree on a plan. Then take two minutes to write down three things: the name of your medicine, your current dose, and how long your skin has been calm. Put the note in your phone or your wallet, and bring it to your next visit. Ask, “Could I step down my dose, and what is our plan if my skin flares?”